Volition is at the forefront of epigenetic immunoassay development, contributing to the drug discovery and development cycle from in-vitro target validation to human clinical trials.
Nu.Q® Discover assays have been validated in preclinical PD studies tracking epigenetic modification levels in response to epigenetic inhibitors with recent data presented at AACR demonstrating a dose-dependent reduction in specific Histone PTM levels by simple liquid biopsy.
Our NETosis assay measures the release of Neutrophil Extracellular Traps, aiding in the assessment of acute inflammatory conditions like sepsis and cancer. Our Ex-vivo – Synthetic Sepsis™ platform is designed to screen NETosis modulators and potential activators, providing ex-vivo human data ahead of First-in-Human (FIH) studies.
Predicine is a molecular insights company committed to advancing biomarker-driven precision medicine. It has developed a breakthrough cell-free DNA and cell-free RNA based liquid biopsy technology for non-invasive cancer profiling, disease monitoring, assessing MRD, and early cancer detection. Predicine partners with leading biopharma companies and hospitals to support global clinical trials and personalized cancer care.
Sanyou Biopharmaceuticals is a CRO company featuring phage display antibody libraries of trillion capacity and offering integrated solutions for innovative antibody drugs that include antibody discovery, efficacy validations and CMC. Currently, the company has 240+ employees, R&D laboratories of 11000 m2 and 300+ clients and partners all around the world.
With over 15 years of experience in genetic and epigenetic clinical research, EpigenDx offers high quality products and laboratory services focused on DNA methylation analysis, gene expression profiling, and mutation analysis. Our scientific teams carefully evaluate each project and establish analysis procedures using best fit technologies, including NGS, Pyrosequencing, RT-PCR, digital PCR, and GeneChip Microarray. Our popular services include Line-1 global methylation tests and Foxp3-TSDR analysis for epigenetic immunotherapy. Our GLP compliant and CLIA certified services make us the perfect partner during pre-clinical research and diagnostic test development.
Cellecta, Inc., founded in 2006, is a trusted provider of functional genomic products and services for loss-of-function and gain-of-function phenotypic screening, cell barcoding as well as gene expression and T-cell and B-cell receptor profiling. This includes design and manufacture of CRISPR and RNAi libraries, lentiviral constructs and cell engineering services as well as NGS profiling assays and spatial transcriptomic services for drug target and biomarker discovery and other applications. For more information visit cellecta.com
Veracyte is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Veracyte also offers a complete range of in vitro diagnostic (IVD) and companion diagnostic development services, allowing us to support biopharmaceutical and diagnostic companies at every stage of their IVD programs.
Canopy Biosciences, a Bruker company, empowers innovation by providing access to cutting-edge spatial biology and multi-omic tools so biomedical researchers can drive scientific discovery faster. Our proprietary technology ChipCytometry™ is a quantitative multiplex immunofluorescence imaging method for the spatial analysis of complex tissues and mapping of cell populations with single-cell resolution. Supported by Canopy Spatial Services™ with our CLIA-certified laboratory, we provide a unique collection of spatial and single-cell technologies that accelerate the understanding of cellular diversity and interaction.
M24You, an exclusive distributor of M2-Automation technology, offers precision and fast microarray instruments with modular dispensing methods and easy-to-exchange dispensers for contact and non-contact liquid handling. The interactive software for superior dispensing quality, stability, QC, and accuracy (CV <=2%) is implemented in each instrument. Our expert team provides bespoke solutions for your applications and optimizes biomolecule binding on target surfaces through precise control of hydrophobicity, temperature, humidity, and more. Rely on M24You to deliver personalized, cutting-edge microarray instruments from R&D to full-scale automated production lines.
ANGLE has worked towards, and received in 2022, US Food and Drug Administration (FDA) clearance for their Parsortix ® PC1 System for use with metastatic breast cancer (MBC) patients. This marks a significant achievement as the first ever FDA cleared product for harvesting circulating tumour cells from MBC patient blood samples for user-validated subsequent analysis. Creating new possibilities in the era of personalised cancer medicine, with the ability to repeat a non-invasive liquid biopsy.
Novogene utilises scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realise their research goals in the rapidly evolving world of genomics. With over 2,000 employees, multiple locations around the world, 37 NGS related patents, and over 670 publications in top tier journal such as Nature and Science, the company has rapidly become a world-leader in NGS services. In this conference, we will exhibit the latest genome sequencing solutions.
Q2 Solutions is a leading global clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions. Q2 Solutions uses global experience, innovation and scientific expertise to transform science and data into medical insights that turn hope into help. A joint venture of IQVIA and Quest Diagnostics, Q2 Solutions leverages each parent organization’s clinical trials laboratory capabilities and treats each sample as if a life depends on it.
Randox Biosciences is dedicated to advancing scientific discovery, drug development and diagnostics. Our aim is to advance the future of personalized approaches and assist Pharma Biotechs and CROs move away from the “one treatment fits all” approach. Our pharma Services division hosts unrivalled expertise in diagnostic and CDx assay development.